Table 4 Medication exposure in SLE patients during 5-year follow-up after THAa
Medication | Infection cases (n = 37) | Non-infection cases (n = 288) | P |
|---|---|---|---|
Steroid | |||
Parenteral | 2 (5.41) | 33 (11.46) | 0.399 |
Oral | 28 (75.68) | 219 (76.04) | 1 |
DMARDs-conventional | |||
Hydroxychloroquine | 16 (43.24) | 174 (60.42) | 0.052 |
Azathioprine | 3 (8.11) | 81 (28.13) | 0.009 |
Mycophenolate mofetil | 0 (0.00) | 9 (3.13) | – |
Ciclosporin | 0 (0.00) | 6 (2.08) | – |
Cyclophosphamide | 2 (5.41) | 10 (3.47) | 0.634 |
Methotrexate | 2 (5.41) | 15 (5.21) | 1 |
DMARDs-biological | |||
Rituximab | 0 (0.00) | 0 (0.00) | |
DMARDs type | 1.38 ± 0.76 | 1.81 ± 0.97 | 0.002 |